Device developer Merxin has announced that a European generics company has acquired exclusive worldwide rights for development of a tiotropium/olodaterol product for the treatment of COPD using Merxin’s MRX004 softmist inhaler. Boehringer Ingelheim markets its tiotropium/olodaterol soft mist inhaler as Stiolto Respimat in the US and Spiolto Respimat in Europe.
Merxin Co-Founder and Director Philippe Rogueda said, “We are delighted with this partnership and the trust that our clients have in our work.”
The MRX004 device is intended for development using the 505j pathway. Over the past few years, Merxin has launched a number of devices for use in development of generic inhalation products, including the MRX001 multidose blister DPI and the MRX003 capsule-based DPI, which received CE marking certification in December 2017.
